Johnson & Johnson: Icotrokinra Delivered an Industry-Leading Combination of Significant Skin Clearance With Demonstrated Tolerability in a Once Daily Pill in Phase 3 Topline Results
November 19, 2024
November 19, 2024
NEW BRUNSWICK, New Jersey, Nov. 19 (TNSres) -- Johnson and Johnson issued the following news release:
* * *
Icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, met its co-primary endpoints in patients with moderate to severe plaque psoriasis
74% of patients achieved clear or almost clear skin (IGA 0/1) at week 24
Comprehensive results are being prepared for presentation at u . . .
* * *
Icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, met its co-primary endpoints in patients with moderate to severe plaque psoriasis
74% of patients achieved clear or almost clear skin (IGA 0/1) at week 24
Comprehensive results are being prepared for presentation at u . . .